These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38542045)

  • 21. Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?
    Martinez-Molina C; Feliu A; Park HS; Juanes A; Diaz-Torne C; Vidal S; Corominas H
    J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673626
    [No Abstract]   [Full Text] [Related]  

  • 22. A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.
    Edwards CJ; Sawant R; Garg V; Du EX; Friedman A; Betts KA
    Rheumatol Ther; 2021 Mar; 8(1):167-181. PubMed ID: 33244703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
    Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
    Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.
    Bergman M; Chen N; Thielen R; Zueger P
    Adv Ther; 2023 Oct; 40(10):4493-4503. PubMed ID: 37542646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice.
    Benucci M; Bardelli M; Cazzato M; Laurino E; Bartoli F; Damiani A; Li Gobbi F; Panaccione A; Di Cato L; Niccoli L; Frediani B; Mosca M; Guiducci S; Cantini F
    J Pers Med; 2023 Aug; 13(9):. PubMed ID: 37763071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy.
    D'Alessandro F; Cazzato M; Laurino E; Morganti R; Bardelli M; Frediani B; Buongarzone C; Moroncini G; Guiducci S; Cometi L; Benucci M; Ligobbi F; Marotto D; Mosca M
    Clin Rheumatol; 2024 Feb; 43(2):657-665. PubMed ID: 38135860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.
    Szekanecz Z; Buch MH; Charles-Schoeman C; Galloway J; Karpouzas GA; Kristensen LE; Ytterberg SR; Hamar A; Fleischmann R
    Nat Rev Rheumatol; 2024 Feb; 20(2):101-115. PubMed ID: 38216757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat.
    Ekin A; Misirci S; Görünen A; Coskun BN; Yagiz B; Dalkilic E; Pehlivan Y
    Med Princ Pract; 2024 Sep; ():1-12. PubMed ID: 39288740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital.
    Ramirez Huaranga MA; Calvo Pascual LA; Velasco Sanchez D; Martin de la Sierra Lopez L; Jimenez Rodriguez L; Lopez Menchero Mora A; Castro Corredor D; Gonzalez Peñas M
    Cureus; 2024 Aug; 16(8):e67729. PubMed ID: 39318929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study.
    Martinez-Molina C; Gich I; Diaz-Torné C; Park HS; Feliu A; Vidal S; Corominas H
    Sci Rep; 2024 Jan; 14(1):172. PubMed ID: 38168532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted.
    Benucci M; Damiani A; Infantino M; Manfredi M; Lari B; Grossi V; Gobbi FL; Sarzi-Puttini P
    Pharmacol Res; 2022 Sep; 183():106359. PubMed ID: 35907434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis.
    Biggioggero M; Becciolini A; Crotti C; Agape E; Favalli EG
    Drugs Context; 2019; 8():212595. PubMed ID: 31692920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
    Scheepers L; Yang Y; Chen YL; Jones G
    Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
    Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
    JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review.
    Boyce EG; Rogan EL; C Lui M
    Ann Pharmacother; 2023 Apr; 57(4):450-462. PubMed ID: 35919945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study).
    Hernández-Cruz B; Rosas J; Díaz-Torné C; Belzunegui J; García-Vicuña R; Inciarte-Mundo J; Pons A; Millán AM; Jeria-Navarro S; Valero JA; García-Castañeda N; Valero C; Llorente I; Calvo A; Díaz-Cerezo S; Núñez M
    Rheumatol Ther; 2022 Apr; 9(2):589-608. PubMed ID: 35041155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis.
    Weng C; Xue L; Wang Q; Lu W; Xu J; Liu Z
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X21999564. PubMed ID: 33815570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Hayashi S; Tachibana S; Maeda T; Yamashita M; Shirasugi I; Yamamoto Y; Yamada H; Okano T; Nishimura K; Ueda Y; Jinno S; Saegusa J; Yamamoto W; Murata K; Fujii T; Hata K; Yoshikawa A; Ebina K; Etani Y; Yoshida N; Amuro H; Hashimoto M; Hara R; Katayama M; Okano T; Kuroda R
    Rheumatology (Oxford); 2024 Nov; 63(11):3033-3041. PubMed ID: 37924201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Balneotherapy (or spa therapy) for rheumatoid arthritis.
    Verhagen AP; Bierma-Zeinstra SM; Boers M; Cardoso JR; Lambeck J; de Bie R; de Vet HC
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD000518. PubMed ID: 25862243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis].
    Zou X; Bai XJ; Zhang LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 55(6):1013-1021. PubMed ID: 38101782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.